| Literature DB >> 29564062 |
Reza Karbalaei1, Marzieh Allahyari2, Mostafa Rezaei-Tavirani1, Hamid Asadzadeh-Aghdaei3, Mohammad Reza Zali4.
Abstract
AIM: Analysis reconstruction networks from two diseases, NAFLD and Alzheimer`s diseases and their relationship based on systems biology methods.Entities:
Keywords: Alzheimer`s disease (AD); Hub-bottlenecks; Non-alcoholic fatty liver disease (NAFLD); Protein clusters; Protein-protein interaction (PPI) network analysis
Year: 2018 PMID: 29564062 PMCID: PMC5849115
Source DB: PubMed Journal: Gastroenterol Hepatol Bed Bench ISSN: 2008-2258
Figure 1Resulted network which is constructed by common genes between NAFLD and AD diseases is presented. This network includes four clusters that are highlighted by different colors. Cluster-1: orange, cluster-2: red, cluster-3: green, and cluster-4: gray
List of enriched pathways based on network clustering related to the common genes between NAFLD and AD is presented. Cluster four does not have has pathways, due to less number of genes
| GO Term | Ontology Source | Adjusted-P Value | Cluster name |
|---|---|---|---|
| regulation of glucose import | GO Biological Process | 1.1E-11 | 1 |
| glucose import | GO Biological Process | 4.5E-14 | |
| AMPK signaling pathway | KEGG | 1.3E-25 | |
| Longevity regulating pathway | KEGG | 5.1E-11 | |
| Adipocytokine signaling pathway | KEGG | 1.7E-20 | |
| fatty acid oxidation | GO Biological Process | 1.4E-14 | |
| PPAR signaling pathway | KEGG | 3.1E-13 | |
| Adipocytokine signaling pathway | KEGG | 1.7E-20 | |
| Insulin resistance | KEGG | 5.8E-23 | |
| regulation of fatty acid metabolic process | GO Biological Process | 4.2E-20 | |
| positive regulation of fatty acid metabolic process | GO Biological Process | 1.3E-14 | |
| fatty acid beta-oxidation | GO Biological Process | 1.4E-11 | |
| long-chain fatty acid metabolic process | GO Biological Process | 1.2E-16 | 2 |
| arachidonic acid metabolic process | GO Biological Process | 4.3E-16 | |
| Metabolism of xenobiotics by cytochrome P450 | KEGG | 5.1E-23 | |
| Drug metabolism | KEGG | 3.3E-23 | |
| Chemical carcinogenesis | KEGG | 6.9E-20 | |
| Oxidation by Cytochrome P450 | WikiPathways | 6.9E-16 | |
| Vitamin D (calciferol) metabolism | REACTOME | 7.5E-16 | |
| Cytochrome P450 - arranged by substrate type | REACTOME | 7.5E-16 | |
| Vitamins | REACTOME | 7.5E-16 | |
| Oncostatin M Signaling Pathway | WikiPathways | 1.4E-28 | 3 |
| Lung fibrosis | WikiPathways | 1.5E-24 | |
| AGE-RAGE signaling pathway in diabetic complications | KEGG | 6.2E-28 | |
| Interleukin-10 signaling | REACTOME | 6E-48 | |
| Interleukin-4 and 13 signaling | REACTOME | 6E-48 | |
| positive regulation of JAK-STAT cascade | GO Biological Process | 4.3E-23 | |
| tyrosine phosphorylation of STAT protein | GO Biological Process | 2E-21 | |
| regulation of tyrosine phosphorylation of STAT protein | GO Biological Process | 1.5E-21 | |
| IL-17 signaling pathway | KEGG | 2.1E-26 | |
| Salmonella infection | KEGG | 7.8E-27 | |
| Pertussis | KEGG | 1.4E-25 | |
| Leishmaniasis | KEGG | 6.5E-28 | |
| Chagas disease (American trypanosomiasis) | KEGG | 7.4E-30 | |
| Inflammatory bowel disease (IBD) | KEGG | 1.7E-26 | |
| Rheumatoid arthritis | KEGG | 1.3E-28 | |
| Allograft Rejection | WikiPathways | 1.2E-21 | |
| lipopolysaccharide-mediated signaling pathway | GO Biological Process | 4.6E-27 |
Hub and Bottleneck genes of Common network genes between NAFLD and AD are shown. Hub-bottleneck genes are bolded
| R | Hubs | Degree | Bottlenecks | Betweenness score |
|---|---|---|---|---|
| 1 | IL6 | 109 | TP53 | 0.087078 |
| 2 | AKT1 | 99 | IL6 | 0.06467 |
| 3 | TP53 | 98 | AKT1 | 0.054262 |
| 4 | TNF | 97 | TNF | 0.047973 |
| 5 | JUN | 89 | JUN | 0.034409 |
| 6 | VEGFA | 83 | PPARG | 0.030972 |
| 7 | PPARG | 79 | INSR | 0.026792 |
| 8 | MAPK3 | 78 | VEGFA | 0.024631 |
| 9 | IGF1 | 77 | LPL | 0.021859 |
| 10 | LEP | 75 | CAT | 0.020219 |
OMIM result from enrichment of Hub-bottleneck genes and their first neighbors are represented
| disease name | Adjusted P-value | Genes |
|---|---|---|
| diabetes | 3.41E-10 | TCF7L2;IL6;ACE;IRS1;HFE;HNF4A;INSR;UCP3;IRS2;PPARG;GCK |
| diabetes_mellitus,_type_2 | 1.35E-09 | TCF7L2;IRS1;HNF4A;INSR;UCP3;IRS2;PPARG;GCK |
| obesity | 3.87E-05 | LEP;UCP3;LEPR;PPARG;PPARGC1B |
| diabetes_mellitus | 4.25E-05 | TCF7L2;IRS1;HNF4A;INSR;IRS2;GCK |